Proton Pump Inhibitors and Lower Serum Ferritin Levels in 171 HFE C282Y Homozygotes in the Hemochromatosis and Iron Overload Screening Study

James C Barton*, Paul C Adams1, Ronald T Acton2, Mark Speechley3, Christine E McLaren4, Gordon D McLaren5, Victor R Gordeuk7 and John H Eckfeldt

1 Southern Iron Disorders Center, Birmingham, Alabama and Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
2 Division of Gastroenterology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada
3 Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
4 Department of Epidemiology & Biostatistics, University of Western Ontario, London, Ontario, Canada
5 Department of Epidemiology, University of California, Irvine, Irvine, California, USA
6 VA Long Beach Healthcare System, Long Beach, California and Division of Hematology/Oncology, University of California, Irvine, Irvine, California, USA
7 Center for Sickle Cell Disease, Howard University, Washington, DC, USA
8 Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA

Abstract

**Background:** In non-screening hemochromatosis patients with HFE C282Y homozygosity who achieve iron depletion, the proton pump inhibitor (PPI) omeprazole decreases non-heme iron absorption from test meals and decreases maintenance phlebotomy requirements. We sought to determine the effect of taking PPIs and histamine H2 receptor antagonists (H2RAs) on serum ferritin (SF) levels in C282Y homozygotes diagnosed in a screening study.

**Methods:** We compared mean SF in 171 homozygotes (60 men, 111 women) who reported taking and not taking PPIs and H2RAs. We performed linear regression on in-screening SF using age, reports of taking PPIs and H2RAs, and free thyroxine levels.

**Results:** Eleven homozygotes (6.4%) took PPIs; twelve (6.7%) took H2RAs. Mean SF values of male and female homozygotes who took PPIs were one-half those of homozygotes without PPI reports, but the differences were not significant. In an initial five-factor regression model, H2RAs and free thyroxine levels were not significant predictors of ln SF. In a final three-factor regression model, taking PPIs was associated with lower ln SF (p=0.0031) after controlling for age and sex. The final model explained 31% of the variance in ln SF. Use of H2RAs was not independently associated with ln SF.

**Conclusions:** Taking PPIs is associated with lower SF levels in HFE C282Y homozygotes diagnosed in screening. Inorganic iron absorption may be decreased in some homozygotes who take PPIs; others who take PPIs may have upper gastrointestinal lesions that lower SF due to blood loss.

Keywords: Ferritin; Hemochromatosis; Histamine H2 receptor antagonist; Iron absorption; Proton pump inhibitor

Introduction

Hemochromatosis associated with homozygosity for the C282Y mutation of the HFE gene on chromosome 6p occurs in 1-6 per thousand whites of northwestern European ancestry. Increased iron absorption and consequent increased storage of iron are the predominant causes of hyperferritinemia in HFE C282Y homozygotes [1,2]. In the population-based HEmochromatosis and IRon Overload Screening (HEIRS) Study [3], elevated serum ferritin (SF) levels were observed in 88% of white men and 57% of white women discovered to have C282Y homozygosity [4].

Absorption of inorganic iron depends on its solubilization by gastric acid [5]. Amidated and non-amidated forms of the hormone gastrin stimulate and potentiate gastric acid secretion, respectively [6]. Non-amidated gastrins require ferric ions for biological activity *in vitro* [6]. Subsequent transport of soluble inorganic iron across the luminal surfaces of absorptive enterocytes depends on divalent metal transporter-1 (DMT1), a pH-dependent metal transporter [7]. In HFE C282Y homozygotes, serum gastrin levels are increased [6] and DMT1 expression is up-regulated [7,8]. These mechanisms could partly account for the increased absorption of inorganic iron in C282Y homozygotes. It is also plausible that decreasing gastric acid secretion could decrease solubilization of inorganic iron, DMT1 activity, and inorganic iron absorption, and decrease the rates of rise of storage iron and SF levels in C282Y homozygotes.

Proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2RAs) decrease gastric acid secretion in short-term studies of persons without hemochromatosis [9-11]. In hemochromatosis patients with C282Y homozygosity previously treated with phlebotomy to achieve iron depletion, the PPI omeprazole decreased the absorption of non-heme iron from test meals and decreased maintenance phlebotomy requirements [12]. Observations regarding the effect of H2RAs on iron absorption or phlebotomy requirements in persons with hemochromatosis are very limited [13]. We postulated that reports of taking PPIs or H2RAs would be associated with lower SF levels in participants in the population-based HEIRS Study who were discovered to have HFE C282Y homozygosity. To test this postulate, we tabulated data on 171 euthyroid participants with HFE C282Y homozygosity. We computed the relationships of reports of taking PPIs or H2RAs to SF levels in specimens obtained at a post-screening clinical evaluation using univariable and multivariable

*Corresponding author: James C. Barton, Southern Iron Disorders Center, Broock-wood Medical Center Drive, Birmingham, USA, E-mail: ironmd@isp.com

Received June 10, 2013; Accepted June 12, 2013; Published July 16, 2013


Copyright: © 2013 Barton JC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Methods. The implications of our results are discussed in the context of mechanisms of iron absorption and causes of hyperferritinemia in C282Y homozygotes.

Methods

Study approval

The local Institutional Review Boards of the HEIRS Study Coordinating Center, Central Laboratory, and each Field Center approved the Study protocol [3]. The Field Centers recruited participant’s ≥25 years of age who gave informed consent.

Selection of study subjects

Participants were recruited from primary care clinics during the interval February 2001-February 2003 at HEIRS Study Field Centers [3,14]. All adult volunteers were eligible to participate in the HEIRS Study, but those who participated only because a family member participated or those who reported on their screening questionnaire that they had been previously diagnosed to have hemochromatosis or iron overload were excluded from the present analysis [15]. All C282Y homozygotes diagnosed in the HEIRS Study were invited to participate in a clinical examination that included listing of participants’ medications, review of the listing by HEIRS Study personnel, and collection of blood samples for additional testing [3,14]. Within, we included observations on euthyroid C282Y homozygotes because a previous report from the HEIRS Study revealed that hypothyroidism or hyperthyroidism affected SF levels significantly [14].

Laboratory methods for SF and serum thyroid-related measures

All measurements were performed at the HEIRS Study Central Laboratory at the University of Minnesota Medical Center-Fairview [3]. SF levels were measured using a turbidometric immunoassay (Roche Diagnostics/Hitachi 911, Indianapolis, IN) [3,14]. The SF reference ranges defined by the HEIRS Study were 15-200 µg/L (women) and 15-300 µg/L (men) [3,14]. Serum concentrations of thyroid-stimulating hormone (TSH) and free thyroxine (T4) were measured using a Siemens/Bayer ADVIA Centaur® immunoassay analyzer (Siemens Corporation, New York, NY) as described elsewhere [14]. Reference ranges were TSH 0.400-5.00 mIU/L and free T4 9.0-23.8 nmol/L [14]. We defined hypothyroidism as having TSH >5.00 mIU/L and free T4 <9.0 nmol/L, and hyperthyroidism as having TSH >0.400 mIU/L and free T4 >23.8 nmol/L, regardless of cause [14].

Medications

Obtaining information about participants’ medications was performed in a prospective manner in the HEIRS Study. Participants brought their prescription and non-prescription medications and supplements to the post-screening clinical examination for review by HEIRS Study personnel. The name of each item was tabulated for the variance in ln SF (Table 2).

Predictors of ln SF in a regression analysis

Straight multiple regression was performed on ln SF using these independent variables: age, sex, use of PPIs, use of H2RAs, and free T4 levels. The respective values of p for these variables were <0.0001, <0.0001, 0.0023, 0.1020, and 0.2435. In a final three-factor model, taking PPIs was independently associated with lower ln SF (p=0.0031) after controlling for the effects of greater age and male sex (both covariates, p <0.0001). The final three-factor model explained 31% of the variance in ln SF (Table 2).

Discussion

A novel finding in the present study is that taking PPIs was a significant independent predictor of lower ln SF levels in 171 HEF C282Y homozygotes diagnosed in the HEIRS Study. This is consistent with a previous report that taking PPIs decreased the absorption of non-herm iron from a test meal and from the habitual diet in hemochromatosis patients with C282Y homozygosity diagnosed in medical care [12]. Achlorhydria or drugs that reduce gastric acid secretion decrease absorption of inorganic iron by reducing its solubility [17,18]. In addition, iron uptake into enterocytes mediated by DMT1
Proton pump inhibitors 405 (4, 45784) 0.7163
Histamine-2 receptor antagonists 763 (385, 1512) 0.7540

Table 2: Parameters of a multiple regression analysis on ln serum ferritin level in 171 HFE C282Y homozygotes.

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Beta coefficient</th>
<th>S.E. (Beta)</th>
<th>t-Value</th>
<th>Value of p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>0.0302</td>
<td>0.0068</td>
<td>4.4211</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male sex</td>
<td>1.22206</td>
<td>0.1800</td>
<td>6.7809</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td>1.0659</td>
<td>0.3555</td>
<td>8.6079</td>
<td>0.0031</td>
</tr>
</tbody>
</table>

*There were 60 men and 111 women. Three men and eight women took proton pump inhibitors. Four men and eight women took histamine receptor-2 antagonists. Results are displayed as geometric means (95% CI). Student's two-tailed t-tests were performed using ln SF values.

Assessment of other potential confounders was beyond the design and scope of the present study. Some disorders, especially common liver conditions, may cause or contribute to hyperferritinenia in persons with or without C282Y homozygosity [26]. The significant negative association of taking PPIs with SF levels that we observed in multiple regression analyses is consistent with the relatively high compliance with and protracted use of PPIs (and H2RAs) for several common therapeutic indications [27-30] and with the measured effects of PPIs on inorganic iron absorption in C282Y homozygotes who had achieved iron depletion with phlebotomy [12]. It is also possible that some of the present C282Y homozygotes who reported taking PPIs or H2RAs had lower SF due to upper gastrointestinal lesions that caused blood loss.

We conclude that taking PPIs is associated with lower SF levels in HFE C282Y homozygotes diagnosed in a screening program. Inorganic iron absorption may be decreased in some homozygotes who take PPIs; others who take PPIs may have upper gastrointestinal lesions that lower SF due to blood loss.

Disclosures

The authors have no conflicts of interest to disclose.

Acknowledgements

Author contributions: All authors contributed substantively to the design and data collection of the HEIRS Study. JCB conceived the present study, performed statistical analyses, and drafted the manuscript. MS and CEM participated in performing statistical analyses. PCA, RTA, CEM, MS, GDM, VRG, and JHE contributed substantive details of the study design, data interpretation, and manuscript formulation. All authors read and approved the final manuscript draft.

Authors’ declarations of personal interests: PCA reports consultancy and research support from Novartis. MS reports ownership of shares of GlaxoSmithKline and consultancy for Merck. GDM reports research funding from Bristol-Myers Squibb, Insys Therapeutics, Inc., Novartis, and Sanofi-Aventis.

Declaration of funding interests

The HEIRS Study was initiated and funded by the National Heart, Lung, and Blood Institute, in conjunction with the National Human Genome Research Institute. The study is supported by contracts N01-HC05185 (University of Minnesota); N01-HC05186, N01-CM-07003-74, and Minority CCOP (Howard University); N01-HC05187 (University of Alabama at Birmingham); N01-C05189 (Kaiser Permanente Center for Health Research); N01-HC05190 (University of California, Irvine); N01-HC05191 (London Health Sciences Centre); and N01-C05192 (Wake Forest University). Additional support was provided by the University of Alabama at Birmingham General Clinical Research Center (GCCR) grant M01-RR00032, Howard University GCCR grant M01-RR10284, and the University of California, Irvine UCS/D/UICI Satellite GCCR grant M01-RR00827, sponsored by the National Center for Research Resources, National Institutes of Health; Howard University Research Scientist Award LH1-HL03679-05 from the National Heart, Lung and Blood Institute and the Office of Research on Minority Health (VRG); and Southern Iron Disorders Center (JCB, RTA).
References


Submit your next manuscript and get advantages of OMICS

Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 250 Open Access Journals
- 20,000,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, BRSOC, Index Copernicus and Google Scholar etc.
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://omicsgroup.info/editorialtracking/vitamin/